Nunn Jason Raleigh
SEC-identified person · CIK 1444319 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Zenas Biopharma, Inc. ZBIO | Director | filed 2024 - 2026 |
| Addex Therapeutics Ltd. ADXN | Director | filed 2026 - 2026 |
| Regulus Therapeutics Inc. RGLS | Director | filed 2019 - 2025 |
| Trevena INC TRVN | Director | filed 2014 - 2024 |
| Dermira, Inc. DERM | Director | filed 2014 - 2020 |
| Trivascular Technologies, Inc. TRIV | Director | filed 2014 - 2015 |
| Hyperion Therapeutics INC HPTX | Director | filed 2012 - 2015 |
| Transcept Pharmaceuticals Inc TSPT | Director | filed 2009 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.